Dr. Andrew Lane discusses the improved outcomes of the Tag-Aza-Ven triplet over standard single-agent therapy for aggressive BPDCN at #ASH2025.
sohoinsider.com/meetings-con...

Enjoy the videos and music that you love, upload original content and share it all with friends, family and the world on YouTube.

#TreatmentTuesdays

The CAMMA-3 study shows that subcutaneous cevostamab demonstrates manageable safety and meaningful clinical activity in relapsed/refractory myeloma.

Dr. Phoebe Joy Ho, speaking at #ASH2025 presents the results of this phase lb study.

Enjoy the videos and music that you love, upload original content and share it all with friends, family and the world on YouTube.

#TreatmentTuesdays

The LINKER-MM4 trial investigates linvoseltamab as a simplified monotherapy option for newly diagnosed myeloma patients
Speaking at #ASH2025 Dr. Xavier Leleu explains the safety & efficacy findings from this new frontline approach

🎬 [REPLAY] Les replays de la Soirée Post-ASH 2025 sont disponibles !

www.youtube.com/playlist?lis...

#ASH #ASH2025 #FSMR #MaladiesRares

📢 The January 2026 EHC Novel #Treatment Review (#NTR) is here! Highlights from #ASH2025, regulatory updates & advances in haemophilia treatment—FVIII mimetics, gene therapy, rebalancing therapies & more. 👏 Thanks to our NTR Working Group! 🔗 buff.ly/q09vsZp

New Study Offers Hope for Better Treatment Strategies: Understanding Blast Phase Chronic Myeloid Leukemia | Cancer News A Cleveland Clinic leukemia expert explains findings from a multicenter study on blast phase CML, exploring treatment strategies, TKIs, transplantation, and global access challenges.

A new multicenter study led by Dr. Akriti Jain sheds light on how blast phase CML is currently treated in the U.S. and which strategies may offer the best outcomes: binaytara.org/cancernews/a...
#LeukemiaResearch #CML #ASH2025 #Hematology #CancerCare #Binaytara

Enjoy the videos and music that you love, upload original content and share it all with friends, family and the world on YouTube.

#TreatmentTuesdays

The inMMyCAR study introduces KLN1010, a novel "in vivo" CAR T-cell therapy that targets BCMA without the need for cell collection & manufacturing. Dr. Phoebe Joy Ho, speaking at #ASH2025 shares promising early results.

Learn more

#ASH2025 highlighted transformative data in #leukemia and myeloproliferative neoplasms. Experts from Cleveland Clinic and Fred Hutchinson noted key findings, such as improved survival with combination therapies in blast-phase CML: buff.ly/EK8dJAi

BrECADD May Be a Standard Therapy Option in Newly Diagnosed, Advanced-Stage HL - Hematology Advisor Researchers compared the safety and efficacy of BrECADD vs eBEACOPP, a standard regimen, in the newly diagnosed, advanced-stage classical HL setting.

Among patients with newly diagnosed, advanced-stage classical #HodgkinLymphoma, the novel BrECADD combination may represent a new standard treatment option. Presented at #ASH25 by @ferdinandusj.bsky.social. From @cancertherapyadv.bsky.social.

https://bit.ly/45HWHVP

#ASH2025 #lymsm

Enjoy the videos and music that you love, upload original content and share it all with friends, family and the world on YouTube.

Highlights from #ASH2025

Dr. Charlotte Pawlyn explains the MajesTEC-3 trial. This showed unprecedented benefits when teclistamab combined with daratumumab is used earlier in the myeloma treatment pathway.

https://f.mtr.cool/lijbryefdl

#TreatmentTuesday #Myeloma

New publication📝 Phase II MITHIC-FL2 first results, presented at #ASH2025, show ORR and CR rates were 92% and 82%, respectively, in patients with ND, high-burden FL treated with mosunetuzumab + zanubrutinib.

Learn more: https://loom.ly/B8pRi7c

#lymphoma #lymsm #MedNews #MedEd

Redoble de tambor... 2 juegos y 12 horas. (9 R.I.P y Fitness Boxing Exercise with Miku)

Favorito de 2025 9 R.I.P 8 horas Horas de juego: Enero 2 Febrero <1 Septiembre 2 Octubre 8

This is low-key embarrassing (also ofc October was the month I played the most, I always pick up 9RIP around that time ausjajd) #Ash2025

At #ASH2025 we interviewed some of the world's leading researchers and clinicians on studies in bispecific antibodies, CAR-T therapy, personalised treatment approaches and more
 
Each Tuesday, we'll be sharing these expert video explanations of key myeloma research as part of  #TreatmentTuesday

Exclusive: Video from ASH 2025 Highlights Webinar Now Available Yesterday, we closed the year with an excellent live webinar reviewing the key scientific highlights from #ASH2025, the world’s leading congress in hematology. VIDEO NOW AVAILABLE!This important session brought together two of the most respected voices in the MPN field: • Prof. Ruben Mesa, internationally recognized MPN expert, President of Advocate Health Cancer Institute and Executive Director of Wake Forest Comprehensive Cancer Center (USA) • Prof. Serge Verstovsek, physician-scientist and le

A new era in MPN therapy is here. 🚀
Replay now available with Prof. Serge Verstovsek + Prof. @rubenmesamd.bsky.social sharing key updates and what’s next in targeted treatments.

🎥 Watch: www.gmpnsf.org/post/exclusive-video-fro...

#ASH2025 #MPNsm

Missed our session on Post #ASH2025 Updates?

🌐 You can access past webinars on #YouTube and on our website—all organized by topic for easy navigation.

🔗 Youtube: youtube.com/@hemehub?si=...

🔗Visit hemehub.org today to learn more!

#Hematology #BloodDisorders #BoneMarrowFailure #HEMEHUB

🧬 Approval based on two studies presented at ASH 2025, highlighting sonrotoclax’s potential as a foundational therapy across B-cell malignancies.

🔗 Read more: bit.ly/ONCOnews07J-04

#ONCOnews #OncoAlert #OncEd #Hematology #Lymphoma #ASH2025 #Oncology

Top anime Medalist 9 Takopii no Genzai 9 Watashi wo Tabetai, Hitodenashi 8 Kimetsu no Yaiba Movie 1: Mugenjou-hen - Akaza Sairai 9 Taiyou yori mo Mabushii Hoshi 8

Villainess top 2% Workplace top 2% Time travel top 5% Shoujo top 5% Adult cast top 5% Seinen top 8% Sports top 9% Mystery top 9% Romance top 14% Drama top 22%

30 anime 214 episodes 88h11min. That's 3.7 days of non-stop anime.

Top anime Medalist Takopii no Genzai Watashi wo Tabetai, Hitodenashi Taiyou yori mo Mabushii Hoshi Total time watched: 3.7 days Mean score: 7.72 Completed anime: 18 Genre bias: Villainess, Workplace, Time travel. Favourite season: Summer.

Also got my MAL wrapped that is not exactly the same as the anilist one lmao
#Ash2025 #AshWrapped #MALWrapUp2025

Days active 101/365 Most active day Mar 21 Status posts made 1 Messages received 11 List activity 228 Sociability Introverted Degeneracy Mild Resolution 2025 N/A Biggest fan No one yet Top anime: 1. Takopii no Genzai 2. Look back 3.Kimetsu no Yaiba Infinity Castle Movie 5. Hikaru ga Shinda Natsu Anime stats: 157 eps watched (-21 from 2024). 19 completed (-2 from 2024). 5 dropped. 0 paused. 77.50 mean score. Top 77% for anime. Top manga: 1. The Spark In Your Eyes 2. Meisou Senshi Nagata Kabi 3. Emerald Midnight's Lover 4. The Dawn to Come 5. Her Tale of Shim Chong Manga stats: 264 chapter read (+100 from 2024). 15 completed (+3 from 2024). 5 dropped. 0 paused. 72.30 mean score. Top 93% manga. Top 87% of anilist. Hottest Take: User has dropped Only Hope.

#Ash2025 #AshWrapped
Got my anilist wrapped akdsfh (why is there a degeneracy level, help)

Our session on Post #ASH2025 Updates is now available to watch anytime!

➡️ Full session: youtu.be/RuuvGWo28OE?...

🌐You can also access previous sessions directly at hemehub.org and on YouTube!

#Hematology #BloodDisorders #Myeloma #BoneMarrowFailure #Lymphoma #Leukemia #MedicalEducation #HEMEHUB

New publication📝 50-month follow-up results from the phase III ECHO trial, presented at #ASH2025, show ABR improved PFS (72.5 vs 47.8 months) vs PBR in older patients with TN MCL.

Learn more: https://loom.ly/B8pRi7c

#lymphoma #lymsm #MedNews #MedEd

Platelet-Activating Anti-HPA-1a Antibodies Drive Pathogenic Mechanisms in FNAIT Only the M-204 anti-HPA-1a antibody triggered FcγRIIa-dependent platelet activation, indicating functional heterogeneity relevant to the severity of FNAIT.

#FNAIT is a potentially life-threatening condition with a distinct subset of HPA-1a antibodies that can directly activate platelets through FcγRIIa. Presented at #ASH2025, from @rarediseaseadvisor.bsky.social.

https://bit.ly/4b8SlKS

#ASH25

Double Agents Infiltrate Cancer Cells, Then Kill Them Call it “Stealth Medicine”: Bispecific agents are sneaking up on cancers and quietly killing them

Cancer drugs that work like double agents?
At #ASH2025, bispecific antibodies showed impressive results in aggressive and indolent lymphomas—especially in older, frailer patients.
@neilosterweil.bsky.social explains: medicalnewsinsider.substack.com/p/double-age...
#CancerCare #Immunotherapy

High Rates of Vulnerability Identified in AML Patients Aged 60 Years or Older High rates of vulnerability on a geriatric assessment were identified in a cohort of fit patients aged 60 years or older with acute myeloid leukemia.

High rates of vulnerability on a geriatric assessment were identified in a cohort of fit patients aged 60 years or older with #AML when measured at baseline, prior to receiving intensive chemotherapy. Presented at #ASH2025.

https://bit.ly/4jiQIMH

#leusm #AMLsm #ASH25

Nurses notice the subtle clues that save lives.

In the upcoming documentary, SICKLE, @Society for Participatory Medicine Board Member Dr. Brenda Merriweather discusses how she assesses patients through their unique body language.

#sicklecellmatters #ASH2025 #SPM #MedSky

ASH 2025: Refining Chemotherapy and Biomarker-Adapted Strategies in AML - Hematology Advisor AML highlights from ASH 2025 include results from the AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.

#AML highlights from #ASH2025 include results from the AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies. From @cancertherapyadv.bsky.social.

https://bit.ly/3LmS7Fx

#AcuteMyeloidLeukemia #leusm

MajesTEC-3 supports teclistamab–daratumumab for relapsed/refractory multiple myeloma Phase 3 trial data show a significant improvement in progression-free survival with use of teclistamab plus daratumumab for patients with relapsed or refractory multiple myeloma.

From #ASH2025 - Phase 3 trial data show a significant improvement in progression-free survival with use of #teclistamab plus #daratumumab for patients with relapsed or refractory #MultipleMyeloma.

👉 buff.ly/7bKRL6f

#OncSky

Secura Bio’s Copiktra PTCL data shines at ASH 2025  The company’s exec talks about how new analyses bolster the case for Copiktra in tough-to-treat lymphomas, informing a pivotal Phase III trial strategy.

New data at #ASH2025 show Secure Bio's Copiktra's (duvelisib) consistent efficacy in heavily pretreated PTCL, with strong signal in AITL informing Phase 3 TERZO trial in nTFHL.
#news #interview #lymphoma #clinicaltrials #oncology

Secura Bio’s Copiktra PTCL data shines at ASH 2025  The company’s exec talks about how new analyses bolster the case for Copiktra in tough-to-treat lymphomas, informing a pivotal Phase III trial strategy.

New data at #ASH2025 show Secure Bio's Copiktra's (duvelisib) consistent efficacy in heavily pretreated PTCL, with strong signal in AITL informing Phase 3 TERZO trial in nTFHL.
#news #interview #lymphoma #clinicaltrials #oncology

Researchers from UChicago Medicine shared key breakthroughs at #ASH2025, including early-line CAR T-cell use in myeloma, novel leukemia studies, outcomes in blood cancers, real-world monoclonal antibody data, and more.
UChicagoBSD @uchicagomedicine.bsky.social
https://ow.ly/EzRt50XNkMZ

Results of ARES: allogeneic microbiotherapy for ruxolitinib-refractory GvHD with GI involvement Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, discusses the Phase III ARES trial (NCT04769895) of MaaT013,...

At #ASH2025, Prof. Florent Malard shared Phase III ARES results with #VJHEMONC, highlighting Xervyteg® (MaaT013) in aGvHD: 62% GI response, 64% ORR and 54% 1-year OS.

👉 Full interview: www.vjhemonc.com/video/xm1_uw...

@ash.hematology.org @vjhemonc.bsky.social